Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF

• Type of Material: Article
• Authors: A.Y Dagnra, Université de Lomé; K.D Mlaga, Medical Research Council Unit, Banjul; K. Adjoh, CHU Sylvanus Olympio; E. Kadanga, Université de Lomé; K. Disse, CHU Sylvanus Olympio; Toidi Adekambi, Emory University
• Language: English
• Date: 2015-11
• Publisher: Wiley
• Publication Version: Final Published Version
• Copyright Statement: Copyright © 2015 The Authors
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.nmni.2015.09.001
• Title of Journal or Parent Work: New Microbes and New Infections
• ISSN: 2052-2975
• Volume: 8
• Start Page: 24
• End Page: 27
• Grant/Funding Information: This work was supported in part by an ASM-UNESCO VRP grant (to TA) and an Emory-CFAR03 developmental grant 00044613 (to TA) from P30AI050409 (to Emory University).
• Research Categories: Health Sciences, Public Health; Health Sciences, Medicine and Surgery

Abstract

Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging